1. Home
  2. news
  3. Small Caps

Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO

Biotech firm also plans to expand its headcount to about 300 in next five years
By Sharanya Pillai
The Business Times
Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO
Prestige Biopharma co-founder Lisa Park says that drug development has always been her "dream and goal". She reckons that the timing is now optimal to pursue an IPO as investor appetite for a biotech play on the Korea Exchange appears buoyant.
20 Jan 2021 - 05:50

Singapore

SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.

BiotechhealthcareIPOSOUTH KOREA

More Stories

Small Caps

Which unicorn listings could GIC and Temasek stand to gain from?

TECH unicorns Gojek, Traveloka and Didi Chuxing are reportedly eyeing the public markets, and they have one thing in common – backing from...

Money

GIC, Temasek poised to reap capital gains bonanza from tech IPO season

SINGAPORE'S sovereign wealth fund GIC and state investor Temasek may make some sweet paper gains as tech firms backed by the two investment giants...

Small Caps

Singapore IPO pipeline looking robust, fuelled by Asia growth and US-China tensions

SINGAPORE may be a laggard in attracting blockbuster listings when compared to Hong Kong, but the pipeline for initial public offerings (IPOs)...